Aprepitant and Calculus prostatic - a phase IV clinical study of FDA data
Summary:
We study 7,061 people who take Aprepitant (aprepitant) or have Calculus prostatic. No report of Calculus prostatic is found in people who take Aprepitant.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Aprepitant?
Aprepitant has active ingredients of aprepitant. eHealthMe is studying from 6,992 Aprepitant users. Check the latest studies of Aprepitant.
What is Calculus Prostatic?
Calculus prostatic (stone in prostate) is found to be associated with 13 drugs and 75 conditions by eHealthMe. Check the latest studies of Calculus prostatic.
No report is found.
Do you take Aprepitant and have Calculus prostatic?
- Check whether Calculus prostatic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Aprepitant:
- Aprepitant (6,992 reports)
Calculus prostatic treatments and more:
- Calculus prostatic (69 reports)
How severe was Calculus prostatic and when was it recovered:
Expand to all the drugs that have ingredients of aprepitant:
Browse all side effects of Aprepitant:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Calculus prostatic:
Browse all the conditions that are associated with Calculus prostatic:
How the study uses the data?
The study uses data from the FDA. It is based on aprepitant (the active ingredients of Aprepitant) and Aprepitant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Atarax and Viibryd - now
- Could Keytruda cause Hypertransaminasaemia? - 3 seconds ago
- Could Viagra cause Weight Increased? - 13 seconds ago
- Drug interactions of Calcitonin-Salmon and Diazepam - 31 seconds ago
- Hair Loss and drugs of ingredients of alemtuzumab - 37 seconds ago
- Could Aggrenox cause Decreased Activity? - 37 seconds ago
- Drug interactions of Vistaril and Docetaxel - 41 seconds ago
- Drug interactions of Levetiracetam and Tadalafil - 41 seconds ago
- Methimazole and Prilosec drug interactions for men aged 60+ - 45 seconds ago
- Could Akineton cause Abdominal Pain Aggravated? - 48 seconds ago